Drug intelligence / Profile preview

Undisclosed Program 2

Development stage: Preclinical
Lead developer: 280Bio
Modality: Small Molecules
Administration: Oral

Overview

Undisclosed Program 2 is an early-stage, orally bioavailable small molecule inhibitor being developed by 280Bio. It is designed to target RAS mutant proteins for the treatment of solid tumors harboring RAS mutations. Currently in the discovery phase, this program is part of 280Bio's broader pipeline focused on the RAS/MAPK pathway, which includes pan-RAS and KRAS-specific inhibitors. As an undisclosed program, specific details regarding its chemical structure or the exact RAS variants it targets have not been publicly released.

Other names: 280Bio-RAS mutant-small molecule-oral-solid tumors with RAS mutations

Targets

HRAS (H-Ras protein)

Beyond the preview

Go deeper on Undisclosed Program 2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Undisclosed Program 2.

Explore the full profile